- Home
- IRWD vs KLAC Comparison
IRWD vs KLAC Comparison
Compare IRWD & KLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- KLAC
- Stock Information
- Founded
- IRWD 1998
- KLAC 1975
- Country
- IRWD United States
- KLAC United States
- Employees
- IRWD N/A
- KLAC N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- KLAC Electronic Components
- Sector
- IRWD Health Care
- KLAC Technology
- Exchange
- IRWD Nasdaq
- KLAC Nasdaq
- Market Cap
- IRWD 150.9M
- KLAC N/A
- IPO Year
- IRWD 2010
- KLAC N/A
- Fundamental
- Price
- IRWD $0.70
- KLAC $703.33
- Analyst Decision
- IRWD Buy
- KLAC Buy
- Analyst Count
- IRWD 5
- KLAC 20
- Target Price
- IRWD $4.94
- KLAC $806.25
- AVG Volume (30 Days)
- IRWD 4.2M
- KLAC 1.2M
- Earning Date
- IRWD 05-07-2025
- KLAC 04-30-2025
- Dividend Yield
- IRWD N/A
- KLAC 0.97%
- EPS Growth
- IRWD N/A
- KLAC 44.11
- EPS
- IRWD N/A
- KLAC 27.49
- Revenue
- IRWD $317,676,000.00
- KLAC $11,550,156,000.00
- Revenue This Year
- IRWD N/A
- KLAC $24.02
- Revenue Next Year
- IRWD N/A
- KLAC $3.11
- P/E Ratio
- IRWD N/A
- KLAC $25.58
- Revenue Growth
- IRWD N/A
- KLAC 20.33
- 52 Week Low
- IRWD $0.59
- KLAC $551.33
- 52 Week High
- IRWD $8.23
- KLAC $896.32
- Technical
- Relative Strength Index (RSI)
- IRWD 29.40
- KLAC 55.36
- Support Level
- IRWD $0.88
- KLAC $675.27
- Resistance Level
- IRWD $0.98
- KLAC $707.84
- Average True Range (ATR)
- IRWD 0.10
- KLAC 18.90
- MACD
- IRWD 0.02
- KLAC 4.46
- Stochastic Oscillator
- IRWD 11.74
- KLAC 93.03
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.